Resources from the same session
Can we stop targeted therapy, immune therapy?
Presenter: V. Grünwald, DE
Session: SESSION 6 - Focus on toxicity and duration of therapy
Resources:
Slides
Webcast
How to handle oligoprogressive disease
Presenter: G. De Velasco, ES
Session: SESSION 6 - Focus on toxicity and duration of therapy
Resources:
Slides
Webcast
New treatments and approaches to NMIBC
Presenter: N. Klümper, DE
Session: SESSION 6 - Focus on toxicity and duration of therapy
Resources:
Slides
Webcast
Participants clinical case discussion: Multidisciplinary management of overlapping hepatotoxicity in a patient with mccRCC during first-line immuno-based treatment
Presenter: E. Tassinari, IT
Session: SESSION 6 - Focus on toxicity and duration of therapy
Resources:
Slides
Webcast
Participants clinical case discussion: Severe combined cardiac and neuromuscular toxicity from 1st line immune-based combination in mRCC: a case report
Presenter: M. Rosellini, IT
Session: SESSION 6 - Focus on toxicity and duration of therapy
Resources:
Slides
Webcast
Participants clinical case discussion: Metastatic clear cell renal cancer: a patient case of exceptional response and uncommon toxicity
Presenter: I. Zerdes, SE
Session: SESSION 6 - Focus on toxicity and duration of therapy
Resources:
Slides
Webcast